O
ARWR icon

OrbiMed’s Arrowhead Research ARWR Stock Holding History

OrbiMed’s Portfolio ARWR Stock Details ARWR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-739,651
Closed -$21.2M – 116
2024
Q1 		$21.2M Buy
739,651
+420,000
+131% +$13.4M 0.39% 62
2023
Q4 		$9.78M Sell
319,651
-114,000
-26% -$3.03M 0.2% 78
2023
Q3 		$11.7M Buy
433,651
+316,651
+271% +$9.7M 0.25% 78
2023
Q2 		$4.17M Buy
+117,000
New +$4.03M 0.08% 107
2020
Q3 		– Sell
-68,100
Closed -$2.94M – 147
2020
Q2 		$2.94M Hold
68,100
– – 0.04% 127
2020
Q1 		$1.96M Buy
+68,100
New +$2.75M 0.03% 127
2016
Q4 		– Sell
-2,159,973
Closed -$15.9M – 133
2016
Q3 		$15.9M Buy
+2,159,973
New +$14M 0.18% 83
2014
Q4 		– Sell
-5,178,200
Closed -$76.5M – 133
2014
Q3 		$76.5M Buy
5,178,200
+220,400
+4% +$3.01M 0.8% 37
2014
Q2 		$70.9M Buy
4,957,800
+1,047,800
+27% +$13.7M 0.83% 38
2014
Q1 		$64.2M Buy
3,910,000
+1,781,100
+84% +$31.3M 0.79% 39
2013
Q4 		$23.1M Buy
+2,128,900
New +$17M 0.34% 59

Other funds holding ARWR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed's ARWR Position: Q2 2024 in Review

OrbiMed sold out of Arrowhead Research (ARWR) in Q2 2024, closing a stake of 739,651 shares — an estimated $21.2M sold.

OrbiMed first reported a position in ARWR in Q4 2013 and held it in 11 quarters. The position peaked at $76.5M in Q3 2014. 272 funds tracked by Wall St. Rank hold ARWR as of Q2 2024.

  • OrbiMed reported no remaining Arrowhead Research position as of Q2 2024 after selling out during the quarter.
  • OrbiMed sold 739,651 Arrowhead Research shares in Q2 2024, an estimated $21.2M.
  • OrbiMed first reported a position in Arrowhead Research in Q4 2013 and held it in 11 quarters.
  • OrbiMed's Arrowhead Research position peaked at $76.5M in Q3 2014.
  • 272 funds tracked by Wall St. Rank held Arrowhead Research as of Q2 2024.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.